Now showing items 1-1 of 1

  • Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. 

    Brown, JR; Moslehi, J; Ewer, MS; O'Brien, SM; Ghia, P; Cymbalista, F; Shanafelt, TD; Fraser, G; Rule, S; Coutre, SE; Dilhuydy, M-S; Cramer, P; Jaeger, U; Dreyling, M; Byrd, JC; Treon, S; Liu, EY; Chang, S; Bista, A; Vempati, R; Boornazian, L; Valentino, R; Reddy, V; Mahler, M; Yang, H; Graef, T; Burger, JA (Wiley, 2019-02)
    Ibrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B-cell malignancies. In ibrutinib clinical studies, low-grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We ...

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV